Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736925 · ClinicalTrials.gov registry record · NA
Omega-3 Fatty Acids and Subconcussive Head Impacts
A NA study of Omega 3 Fatty Acids and Subconcussive Head Impact, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 208
- Enrollment target
- 1
- Study location
NCT06736925: Recruiting NA study of Omega 3 Fatty Acids and Subconcussive Head Impact, sponsored by Indiana University.
NCT06736925 is a NA study of Omega 3 Fatty Acids and Subconcussive Head Impact that is actively recruiting participants, run by Indiana University. The registered enrollment target is 208 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736925, a NA study of Omega 3 Fatty Acids and Subconcussive Head Impact, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 208 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the proposed double-blind, randomized placebo-controlled trial is to understand how supplementation with fish oil \[docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)\] promote brain health against soccer heading. The study involves taking DHA+EPA or placebo, questionnaires, blood draws, brain imaging, tests to evaluate heart function, and soccer headings.
Primary Outcome
The primary outcome analyses will be comparing group differences (group x time interactions) in blood biomarkers, specifically NF-L (neurofilament light, ), tau (picogram per milliliter), GFAP (glial fibrillary acidic protein; nanograms per milliliter), UCH-L1 (ubiquitin C-terminal hydrolase-L1; picograms per milliliter), and S100B (S100 calcium binding protein B; nanograms per milliliter). The aggregation of all blood biomarkers will provide a comprehensive overview of the biofluid profile of t
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Omega-3 Fatty Acids (EPA plus DHA)
- DIETARY_SUPPLEMENT Organic soybean oil
- OTHER Soccer Heading Model
Study Locations (1)
Indiana
- Indiana University School of Public Health - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2029-05-31 |
| Phase | NA |
What NCT06736925 shows while recruiting
NCT06736925 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Omega 3 Fatty Acids appearing as the primary indexed condition, and to 3 interventions - of which Omega-3 Fatty Acids (EPA plus DHA) is the first listed.
NCT06736925 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06736925 about?
NCT06736925 is a clinical study titled "Omega-3 Fatty Acids and Subconcussive Head Impacts". The purpose of the proposed double-blind, randomized placebo-controlled trial is to understand how supplementation with fish oil \[docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)\] promote brain health against soccer heading. The study involves taking DHA+EPA or placebo, questionnaires, b...
What is the current status of trial NCT06736925?
This trial is currently recruiting. It is a NA study. The enrollment target is 208 participants. The study started on 2025-02-28. Estimated completion is 2029-05-31.
What conditions does trial NCT06736925 study?
This clinical trial studies the following conditions: Omega 3 Fatty Acids, Subconcussive Head Impact.
What interventions are being tested in trial NCT06736925?
The interventions under investigation include: Omega-3 Fatty Acids (EPA plus DHA) (DIETARY_SUPPLEMENT), Organic soybean oil (DIETARY_SUPPLEMENT), Soccer Heading Model (OTHER).
Who is sponsoring clinical trial NCT06736925?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736925 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Omega 3 Fatty Acids
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06736925's enrollment target sits among peer trials
208 496th of 2000 higher than 1,502 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI